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Injurious Falls and Syncope inOlder
Community-Dwelling AdultsMeeting Inclusion
Criteria for SPRINT
The Systolic Blood Pressure Intervention Trial (SPRINT) dem-
onstrated that treating adults 75 years of age or older with hy-
pertension to reacha systolic bloodpressure target of less than
120 mmHg compared with a systolic blood pressure target of
less than 140 mm Hg reduced the numbers of cardiovascular
events and deathwithout a significant increase in the number
of injurious falls or syncope.1However, prior to theadoptionof
an intensivestrategy to lowersystolicbloodpressure in theold-
est segment of the population, it is prudent to determine if in-
dividualsmeeting inclusioncriteria forSPRINToutsidetheclini-
cal trial context are similar to trial participants, especiallywith
regard to risk for adverse outcomes. We used The Irish Longi-
tudinal Study on Ageing2,3 (TILDA) to compare baseline rates
of injurious falls and syncope in community-dwelling older
adults with the rates in the standard care group of SPRINT.
Methods | The Irish Longitudinal Study on Ageing is a nation-
ally representative prospective cohort study of community-
dwelling adults 50 years of age or older in the Republic of
Ireland.2,3Randomsamplingofgeographical clusterswasused
to select households. Data collection involved an in-home in-
terview, a self-completedquestionnaire (N = 8175), andacom-
prehensive health assessment (N = 5751). Mean follow-up for
TILDAwas 3.4 years, compared with amedian of 3.4 years in
SPRINT. Our study used data from wave 1 of TILDA (com-
pleted July 31, 2011) to retrospectively identify participants
meetingfinal inclusioncriteria forSPRINT.Outcomeswerethen
reportedatwave2 (February 1, 2012-March31, 2013) andwave
3 (March 1, 2014-December 31, 2015) follow-up. Ethical ap-
proval for TILDA was obtained from the Faculty of Health
Sciences Research Ethics Committee at Trinity College Dub-
lin. All participants provided written informed consent.
We used the SPRINT eligibility criteria to identify TILDA
participants whowould be eligible for the trial.1,4; all SPRINT
eligibility parameters apart from degree of proteinuria were
available for TILDA participants. Falls and syncope were as-
sessed either by self-report or proxy at each wave. Partici-
pants were asked if they had fallen since their last interview
and, if so, if they injured themselves seriously enough toneed
medical treatment. These questions were repeated for syn-
cope. All analyses were performed using R statistical soft-
ware (R Foundation for Statistical Computing) and Stata, ver-
sion 14.1 (StataCorp), incorporating inverse probability
weighting to account for complex surveydesigns.P < .05was
considered significant.
Results |TheTable5displaysacomparisonof characteristicsbe-
tweenTILDAparticipantsmeeting inclusioncriteria for thesub-
groupof SPRINTparticipantswhowere75yearsof ageorolder
and those of participants in the standard care armof SPRINT.1
All 407 participants in TILDA were white, as opposed to par-
ticipants in SPRINT (987 of 1319 [74.8%]). Orthostatic hypo-
tension at baseline was more common in TILDA participants
than SPRINT (50 of 407 [12.3%] vs 124 of 1319 [9.4%]).2,3 His-
toryof cardiovasculardisease (309of 1319 [23.4%]vs72of407
[17.7%]), as well as rates of aspirin (765 of 1319 [58.0%] vs 160
of 407 [39.3%]) and statin use (697 of 1319 [52.8%] vs 159 of
407 [39.1%]), were higher in SPRINT participants, suggesting
a higher cardiovascular risk profile.While the 407TILDApar-
ticipantswereundergoing standard care in the community for
a similar duration of follow-up, 111 (27.3%) reported an inju-
rious fall and54 (13.3%) reportedsyncope. InSPRINT,73of 1319
participants (5.5%) reported injurious falls and32of 1319 (2.4%)
reported syncope (Figure).
Discussion | Inacommunity-basedprospectivecohortwithcon-
temporaneous follow-upof comparableduration (TILDA),par-
ticipants 75 years of ageor olderwhomet inclusion criteria for
SPRINT had rates of injurious falls and syncope approxi-
mately 5-fold higher than the standard care group in SPRINT.
Given the high baseline rates of falls and syncope, any in-
crease in these rates due to intensive treatment of hyperten-
sion could result in harm.
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Table. Characteristics of Community-Dwelling TILDA ParticipantsMeeting SPRINT Inclusion Criteria
vs SPRINT Participants
Characteristic
TILDA Participants
Aged ≥75 y Meeting
Inclusion Criteria
for SPRINT
(N = 407)
SPRINT Participants
Aged ≥75 y
(N = 1319)
Female sex, No. (%) 239 (58.7) 501 (38.0)
Age, mean (SD), y 80.1 (6.1) 79.9 (4.1)
Race/ethnicity, No. (%)
White 100 987 (74.8)
Black or African American 0 226 (17.1)
Hispanic 0 85 (6.4)
Other 0 21 (1.6)
Seated blood pressure, mean (SD), mm Hg
Systolic 148.1 (14.1) 141.6 (15.8)
Diastolic 82.0 (10.1) 70.9 (11.0)
Orthostatic hypotension, No. (%)a
No 357 (87.7) 1195 (90.6)
Yes 50 (12.3) 124 (9.4)
Serum creatinine, median (IQR), mg/dLb 0.94 (0.81-1.12) 1.1(0.9-1.3)
Estimated GFR, mean (SD), mL/min/1.73 m2c 65.1 (19.9) 63.3 (18.3)
History of cardiovascular disease, No. (%)
No 335 (82.3) 1010 (76.6)
Yes 72 (17.7) 309 (23.4)
Statin use, No. (%)
No 248 (60.9) 622 (47.2)
Yes 159 (39.1) 697 (52.8)
Aspirin use, No. (%)
No 247 (60.7) 554 (42.0)
Yes 160 (39.3) 765 (58.0)
Total cholesterol, mean (SD), mg/dLd 185.3 (38.6) 181.8 (38.7)
Triglycerides, mean (SD), mg/dLd 137.2 (84.0) 99.0 (72.0-134.5)e
HDL cholesterol, mean (SD), mg/dLd 59.5 (17.4) 55.7 (14.9)
Body mass index, mean (SD)f 28.0 (5.0) 27.7 (4.6)
Gait speed, median (IQR), m/sg,h 1.17 (1.05-1.32) 0.92 (0.77-1.06)
>0.8 m/s, No. (%) 389 (95.5) 950 (72.0)
<0.8 m/s, No. (%) 18 (4.5) 369 (28.0)
Frailty, No. (%)i
Not frail (TILDA) or fit (SPRINT) 147 (36.1) 190 (14.4)
Prefrail (TILDA) or less fit (SPRINT) 221 (54.3) 745 (56.5)
Frail 39 (9.6) 375 (28.4)
Abbreviations: GFR, glomerular
filtration rate; HDL, high-density
lipoprotein; IQR, interquartile range;
SPRINT, Systolic Blood Pressure
Intervention Trial; TILDA, The Irish
Longitudinal Study on Ageing.
SI conversion factors: To convert
creatinine to micromoles per liter,
multiply by 88.4; to convert total and
HDL cholesterol to millimoles per
liter, multiply by 0.0259; and to
convert triglycerides to millimoles per
liter, multiply by 0.0113.
a Criterion for orthostatic
hypotension was a decrease in
systolic blood pressure of 20mm
Hg or more or a decrease in diastolic
blood pressure of 10mmHg or
more after standing.
bA total of 55 participants were
missing data.
c Estimated using Modification of Diet
in Renal Disease.
dA total of 30 participants were
missing data.
e Reported as median (IQR).
f Calculated as weight in kilograms
divided by height in meters
squared.
g A total of 160 participants were
missing data.
h In TILDA, gait speed wasmeasured
using GAITRite portable electronic
walkway system (CIR Systems Inc).
Participants were instructed to walk
at their usual pace along a 4.88-m
walkway. They started walking 2.5
m before the walkway to allow for
acceleration and finished walking 2
m after the walkway to allow for
deceleration. Themean gait speed
from 2walks was recorded in units
of centimeters per second. In
SPRINT, gait speed wasmeasured
via a timed 4-mwalk performed at
the participant’s usual pace from a
standing start.1
i Frailty in TILDA determined by Freid
criteria5; frailty in SPRINT
determined by SPRINT-specific
frailty index.
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ASurvey of UnregulatedDirect-to-Consumer
Treatment Centers Providing StemCells
for PatientsWithHeart Failure
Stem cell therapy for the treatment of heart failure (HF) is
under investigationbutnot approvedby theUSFoodandDrug
Administration (FDA).1 Nevertheless, through direct-to-
consumer promotion, “stem cell centers” claim to offer this
treatment to patients. We sought to assess the type of treat-
ments, cost, and statements made about efficacy.
Methods | Stem cell centers marketing treatment for HF were
identified using a published database.2 We used a standard-
ized script in a telephone survey to ensure consistency indata
collection. Several centers hadmultiple satellite locations; for
these,only1wascontacted. Inquiries includedstemcell source,
infusion method, treatment number, preprocedural evalua-
tion, follow-up, andprice. Representative statements by stem
cell center personnel were chronicled. The board certifica-
tions of physicians namedon centerwebsiteswere compared
against online registries.3,4
Standard descriptive statistics were used (IBM SPSS
Statistics for Windows; version 24.0). For centers that pro-
vided a range (n = 5), the mean of the minimum and maxi-
mumpricewas calculated. The studywas deemed exempt by
the Saint Louis University institutional review board.
Results |Of 61 centers listed as offering HF therapy in 2016,2 15
were satellite sites. Seven centers no longer had active web-
sites or had been closed by the FDA; 2 could not be contacted;
2 refused to provide data; 3 did not offer HF treatment despite
online claims; 1 did not offer treatment for severeHF; and 1 re-
quired advance payment ($250) for telephone consultation.
Half of the remaining 30 centers responding to the survey
were located in 3 states (8 in California, 4 in Florida, and 3 in
New York). The self-reported number of procedures per-
formed varied widely; 5 claimed more than 100. Medical rec-
ords were required at only 9 centers, and a cardiologist’s note
was requested at 6.Noneof the sites discussedmethodologies
used to isolate or identify stem cells; most claimed to use
autologous stem cells alone (24 adipose-derived, 1 from bone
marrow), 2 treatedwith allogeneic stemcells (umbilical or pla-
cental), and 3 offered multiple sources. Stem cells were deliv-
ered intravenously in 29 centers; 1 performed direct coronary
infusion. Stem cells were infused on the same day as harvest
inall centersofferingautologous infusions;6offeredcell bank-
ing.Ancillarytreatments (vitamininfusionsandhyperbaricoxy-
gen) were offered in 5. Follow-upwas required at 2 centers.
The mean (SD) price for a single treatment was $7694
($2737) for autologous and $6038 ($3145) for allogeneic cells.
Adiscount ($500)wasofferedat 2 centers if theprocedurewas
paid for in cash; additional procedures were offered for a dis-
counted price (7 centers; mean discount, $3893 [$888]).
From 39 centers withwebsites advertising HF treatment,
79 physicians were identified: board certified in cardiology
(n = 1), board certified in another field (n = 55), and unveri-
fiedboardcertificationstatus (n = 13).Tenhadno formalmedi-
cal training butweredescribed as “naturopathicmedical doc-
tors.”Characteristic statements recordedduring the telephone
survey are shown in the Box.
Discussion | A recent analysis identified 570 businesses in the
UnitedStatesengaged indirect-to-consumermarketingofstem
cell interventions including centerspurported toprovide stem
cells for cardiac repair2 topatientswithHFdespite lackofFDA
approval. We found that such treatment is delivered without
rigorouspreprocedural evaluations or postprocedural follow-
up.Mostphysicianswerenotboardcertified incardiology.The
reasonswhy these businesses can continue to operate are not
clear; in a recent publication, the former FDA commissioner
did not address the FDA’s role,5 though some monitoring of
these businesses does occur.6
Limitations. The surveywas restricted to US sites only; never-
theless, the issue is global.7 Information derived in this study
cannot be independently verified; however, the data pro-
vided are largely unavailable onwebsites and are not publicly
reported.
Given the prognosis of advanced heart failure and rela-
tively limited options, clinicians need to be aware that pa-
tients may seek out this option and thereby may expose
Figure. Comparison of the Prevalence Rates of Injurious Falls
and Syncope Between the Systolic Blood Pressure Intervention Trial
(SPRINT) and The Irish Longitudinal Study on Ageing (TILDA)
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Outcome prevalence is reported while also accounting for the attrition rate over
the course of the study. Between wave 1 and wave 2 of TILDA, 46 of 407
participants (11.3%) were no longer participating in the study owing to death
(n = 21), loss to follow-up (n = 2), refusal to answer questions as part of the
study (n = 22), or withdrawal from the study (n = 1). Between wave 2 and wave
3, 109 of 407 participants (26.8%) were no longer participating in the study.
Ascertainment of the reasons for this attrition at wave 3 is currently still ongoing
at the time of writing.
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